Fulgent Genetics, Inc. FLGT Therapeutic Development — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s therapeutic development — research and development expense?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — research and development expense of $4.18M in Q1 2026.
- How has Fulgent Genetics, Inc.'s therapeutic development — research and development expense changed year-over-year?
- Fulgent Genetics, Inc.'s therapeutic development — research and development expense increased by 4.7% year-over-year, from $3.99M to $4.18M.
- What is the long-term trend for Fulgent Genetics, Inc.'s therapeutic development — research and development expense?
- Over 3 years (2022 to 2025), Fulgent Genetics, Inc.'s therapeutic development — research and development expense has grown at a 194.4% compound annual growth rate (CAGR), from $746K to $19.04M.
- What does therapeutic development — research and development expense mean?
- This captures the costs associated with the research and development activities aimed at discovering or improving drug candidates within the therapeutic development segment. It is a critical indicator of the company's commitment to long-term innovation and future product pipeline viability.